03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
18:10 , Mar 9, 2018 |  BC Week In Review  |  Financial News

Acacia raises €40M in IPO

Acacia Pharma Group plc (Euronext:ACPH) raised €40 million ($49.3 million) on March 2 through the sale of 11.1 million shares at €3.60 in an IPO underwritten by Bank Degroof Petercam NV/SA and RBC Europe. The...
20:14 , Mar 2, 2018 |  BC Extra  |  Financial News

Acacia raises €40M in IPO

Acacia Pharma Group plc (Euronext:ACPH) raised €40 million ($49.3 million) through the sale of 11.1 million shares at €3.60 in an IPO underwritten by Bank Degroof Petercam NV/SA and RBC Europe. The price values the...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
17:38 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

FDA reviewing Acacia's PONV therapy

Acacia Pharma Group Ltd. (Cambridge, U.K.) said FDA accepted for review an NDA for Baremsis amisulpride (formerly APD421), alone and in combination with other antiemetics, as treatment and prophylaxis for postoperative nausea and vomiting (PONV)....
08:03 , Jan 4, 2018 |  BC Extra  |  Company News

FDA reviewing Acacia's PONV therapy

Acacia Pharma Group Ltd. (Cambridge, U.K.) said FDA accepted for review an NDA for Baremsis amisulpride (formerly APD421), alone and in combination with other antiemetics, as treatment and prophylaxis for postoperative nausea and vomiting. The...
21:07 , Apr 27, 2017 |  BC Week In Review  |  Clinical News

Baremsis: Ph III data

In February, Acacia reported data from a double-blind, international Phase III trial in 705 evaluable patients with established PONV despite receiving prior antiemetic prophylaxis showing that IV Baremsis met the primary endpoint of a greater...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

IV Baremsis amisulpride: Phase III data

A double-blind, international Phase III trial in 568 patients with established PONV who had not received prior antiemetic prophylaxis showed that 2 dose levels of a single dose of IV Baremsis each met the primary...
07:00 , Aug 12, 2016 |  BC Extra  |  Clinical News

Acacia's PONV therapy passes latest Phase III test

Acacia Pharma Group plc (Cambridge, U.K.) said Baremsis IV amisulpride (formerly APD421) met the primary endpoint in a Phase III study to treat postoperative nausea and vomiting (PONV). Compared with placebo, both Baremsis doses led...
07:00 , Mar 28, 2016 |  BC Week In Review  |  Clinical News

IV Baremsis amisulpride: Phase III started

Acacia began a double-blind, placebo-controlled, international Phase III trial to evaluate 2 doses of IV Baremsis in about 560 postsurgical patients who develop PONV despite receiving antiemetic prophylaxis before surgery. Acacia Pharma Group plc, Cambridge,...